Skip to content
Hair Pipeline
← Back to the pipeline

Ivarmacitinib (ARQ-252)

Filed with regulatorOralJAK inhibitor

No public activity in over 18 months

Developed by
Unknown
Current phase
Filed with regulator

Submitted to a regulator and awaiting a decision.

Indications
Alopecia areata
Also known as
ARQ252, SHR0302
Last public activity
September 2023
Record confidence
Medium

Development history

  1. Phase 2Phase 3

    First Phase 3 trial on record: NCT05470413 — Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

    ClinicalTrials.gov ↗
  2. Phase 2

    First Phase 2 trial on record: NCT04346316 — A Phase II Study in Patients With Alopecia Areata

    ClinicalTrials.gov ↗

Registered trials

Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.

  • NCT05470413Phase 3UNKNOWN

    Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

    Reistone Biopharma Company Limited · n=330 · April 2022

  • NCT04346316Phase 2COMPLETED

    A Phase II Study in Patients With Alopecia Areata

    Reistone Biopharma Company Limited · n=94 · May 2020

Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.

Sources